Cardio-oncology最新文献

{"title":"Temporal trends in cardiac arrest and cancer-related mortality among adults in the United States, 1999-2023.","authors":"Reja Ahmad, Muhammad Salik Uddin, Urooj Amjad, Hasibullah Aminpoor, Muhammad Ahsan, Aafia Imran, Muhammad Zubair Farooq, Abdur Rafay Bilal, Asim Sajjad, Muhammad Ahmed, Muhammad Mubariz, Saad Ahmed Waqas","doi":"10.1186/s40959-026-00483-1","DOIUrl":"10.1186/s40959-026-00483-1","url":null,"abstract":"<p><p>BACKGROUND: Cardiac arrest (CA) remains a major contributor to cardiovascular-related mortality in the United States. The coexistence of cancer significantly exacerbates overall disease burden. This study investigates CA and cancer-related trends and demographic disparities in adults from 1999 to 2023. METHODS: This retrospective analysis of CDC WONDER data investigates the trends in mortality associated with CA in patients with cancer. Using Joinpoint regression analysis, the study calculated age-adjusted mortality rates (AAMR) per 100,000 individuals and corresponding annual percentage changes (APC), along with 95% confidence intervals. RESULTS: Between 1999 and 2023, CA and cancer–related mortality accounted for 1,503,315 deaths. With an AAPC of -2.3 (95% CI: -2.4 to -2.1, p < 0.001), the overall AAMR decreased from 37.3 in 1999 to 21.1 in 2023. Adult men had higher AAMRs than women (men: 48.4; women: 30.4) in 1999 to (men: 25.7; women: 17.8) in 2023, with decline for both sexes [men: AAPC: -2.5, p < 0.001; women: AAPC: -2.2, p < 0.001]. AAMRs varied significantly by race, for NH Black individuals (57.6 to 28.1), NH American Indians (22.1 to 15.5), Hispanics (44.6 to 24.7) and NH Whites (34.4 to 19.5) from 1999 to 2023 respectively. The greatest decline in AAMR was observed in middle-aged adults (AAPC: -2.3, p < 0.001). Regionally, the highest decline was seen in South region (AAPC: -3.3, p < 0.001). AAMRs varied by state, from 5.2 in West Virginia to 55.3 in California during 2023. CONCLUSION: This study reveals significant demographic and geographic disparities in CA and cancer-related mortality in U.S. adults from 1999 to 2023, with a disproportionately high burden observed among older adults, males, and NH Black individuals. These findings underscore the urgent need for targeted, equity-driven public health strategies for high-risk groups. </p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13191940/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiotoxicity prevention trials in the era of contemporary cancer therapies: a systematic review.","authors":"Malak Munir, Ahmed Sayed, Sanam Ghazi, Eric H Yang, Avirup Guha, Narendranath Epperla, Daniel Addison","doi":"10.1186/s40959-026-00464-4","DOIUrl":"10.1186/s40959-026-00464-4","url":null,"abstract":"<p><p>BACKGROUND: Cardiovascular toxicity is an increasingly important limitation of effective contemporary cancer therapies. Yet, the extent to which trials focus on preventing cardiotoxic events in patients receiving contemporary therapies is unknown. METHODS: Leveraging PubMed, CENTRAL, clinicaltrials.gov, and publicly available reviews to identify all randomized controlled trials (RCTs) testing interventions for prevention or management of cardiotoxicity in cancer patients through 2024, we assessed the proportion of cardiotoxicity prevention trials that studied contemporary cancer therapies (biologic, targeted, or immune-based therapies). We included RCTs of interventional therapies/strategies against cardiotoxicity during cancer treatment. Data on trial baseline characteristics, design, funding, and reporting were extracted. Regression models were used to define trial and population factors associated with drug selection, reporting bias, and subsequent translation into guidelines. RESULTS: Overall, there were 126 trials, evaluating 15 prevention strategies, enrolling 16,111 participants (45.6 ± 13.9 years, 81.3% female, median trial duration of 23 months). Among trials, 17.5% evaluated patients receiving biologic, targeted, and/or immune-based therapies, including 2.4% of trials focused on immune-based therapies (one IL-2 and two immune checkpoint inhibitors). Most trials (109 [86.5%]) used surrogate endpoints. Over time, there was no temporal increase in the proportion of trials assessing biologic, targeted, or immune-based cancer therapies. CONCLUSION: Collectively, these data suggest that among trials focused on preventing cardiotoxicity, contemporary cancer therapies were not frequently evaluated. </p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13220620/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147662312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finding ferritin footprints in 5-fluorouracil-induced cardiotoxicity.","authors":"Grace M Ferri, Manuel Urina-Jassir, Alexander V Stanisic, Jack M Hensien, Grace Lee, Neal Sullivan, Omar K Siddiqi","doi":"10.1186/s40959-026-00452-8","DOIUrl":"10.1186/s40959-026-00452-8","url":null,"abstract":"<p><p>Fluoropyrimidines, including 5-fluorouracil (5-FU), used in the treatment of patients with gastrointestinal malignancies, are associated with cardiotoxicity. Although the mechanism of this cardiotoxicity remains unknown, rat models treated with 5-FU have higher iron concentrations in myocardial tissue compared to controls. As a result, we sought to examine whether ferritin could be a clinical biomarker of cardiotoxicity among patients receiving 5-FU-based chemotherapy. We conducted a retrospective chart review on adult patients receiving 5-FU-based intravenous chemotherapy at a single academic center from June 2022 to 2024. Potential cardiotoxicity was defined by obstructive coronary artery disease, new wall motion abnormalities on transthoracic echocardiography (TTE), left ventricular ejection fraction decrease ≥10% from pre-treatment TTE, coronary vasospasm, pericardial effusion, or incident heart failure. Of our 93 patients, those with ferritin ≥ 100 ng/mL were nearly 5 times as likely to exhibit potential cardiotoxicity (adjusted odds ratio [aOR] 4.7, confidence interval [CI] 1.0-23.5) (Fig. 1A). Similarly, patients with ferritin ≥ 100 ng/mL were approximately 3 times as likely to experience treatment failure (aOR 3.2, CI 1.1-9.7). Based on the apparent relationship between ferritin ≥100 ng/mL, cardiotoxicity, and treatment outcomes, we encourage oncologists to routinely obtain iron studies in addition to pre- and post-treatment TTE among patients receiving 5-FU.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":"12 1","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13067715/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147653853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes associated with left atrial appendage occlusion in patients with cancer-associated atrial fibrillation: a real-world propensity-matched analysis.","authors":"Rochell Issa, Tess Calcagno, Ryan Issa, Rohan Prasad, Patrick Collier, Arianne Agdamag, David C Kaelber, Diego Sadler, Alok A Khorana, Mohamed Kanj, Rohit Moudgil","doi":"10.1186/s40959-026-00478-y","DOIUrl":"10.1186/s40959-026-00478-y","url":null,"abstract":"<p><strong>Background: </strong>Atrial fibrillation (AF) is a common comorbidity in cancer patients, increasing their risk of stroke and mortality. Cancer patients are often excluded from risk stratification models such as HAS-BLED and CHA₂DS₂-VASc, which may underestimate AF-related risks. Additionally, oral anticoagulation in this population increases bleeding risk. This study evaluated the role of left atrial appendage occlusion (LAAO) in cancer patients with AF.</p><p><strong>Methods: </strong>TriNetX, a global federated health research network, was used to identify cancer patients with AF, with and without LAAO, from 2015 to 2023. Propensity score matching (1:1) was performed for age, race, sex, comorbidities, and medication use, generating two equal cohorts of 1,228 patients. The primary endpoint was major bleeding; the secondary endpoints were ischemic stroke and all-cause mortality. Secondary analyses compared LAAO with direct oral anticoagulants (DOACs) and warfarin.</p><p><strong>Results: </strong>Among 2,456 matched AF patients, 1,228 underwent LAAO. LAAO was correlated with significantly lower major bleeding at 3 months (26.4% vs. 33.0%, p < 0.001), with similar trends at 1 year (p = 0.019) and 3 years (p = 0.005). Compared to warfarin, LAAO had lower major bleeding (p = 0.006); rates were similar to DOACs (p = 0.356). Ischemic stroke rates were not significantly different between groups at any time point. LAAO recipients exhibited lower mortality at 3 months (3.6% vs. 15.3%, p < 0.0001), 1 year (11.1% vs. 29.7%, p < 0.001), and 3 years (23.5% vs. 36.9%, p < 0.001). Mortality was also lower in LAAO recipients compared with DOAC (p < 0.001) and warfarin (p < 0.001) groups. In adjusted Cox models, LAAO remained associated with significantly lower mortality (adjusted HR 0.63), while adjusted risks of major bleeding and ischemic stroke did not differ between groups.</p><p><strong>Conclusions: </strong>In cancer patients with AF, LAAO was correlated with lower major bleeding and mortality in matched analyses, while stroke rates were similar. In adjusted Cox models, LAAO remained correlated with lower mortality, whereas bleeding and stroke risks were not significantly different. These findings should be interpreted in the context of real-world treatment selection and the absence of granular data on cancer stage, disease activity, timing of LAAO, and cause-specific mortality.</p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147637523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends, cardiovascular complications, and outcomes in patients receiving CAR T-cell therapy: a 6-year nationwide analysis.","authors":"Karnav Modi, Himil Mahadevia, Raj Shah, Deepthi Vodnala, Talal Asif, Taiyeb Khumri, Furha Cossor","doi":"10.1186/s40959-026-00471-5","DOIUrl":"10.1186/s40959-026-00471-5","url":null,"abstract":"<p><p>BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed or refractory hematologic malignancies. However, real-world data describing cardiovascular complications with CAR T-cell therapy remain limited. METHODS: Using the National Inpatient Sample, we identified hospitalizations involving CAR T-cell therapy from 2017 to 2022. Temporal trends, in-hospital mortality, cardiovascular complications, and other clinical outcomes were evaluated using survey-weighted regression models. RESULTS: Among 13,370 weighted hospitalizations, CAR T-cell use increased from 70 cases in 2017 to 4,335 in 2022. The overall in-hospital mortality rate was 3.4%. Cardiovascular complications were observed in a subset of patients, including arrhythmias in 20.2%, acute myocardial infarction in 0.5%, stroke in 1.0%, cardiogenic shock in 0.2%, and major adverse cardiovascular and cerebrovascular events in 4.5%. Atrial fibrillation was the most common arrhythmia (11.1%), followed by conduction abnormalities (3.9%). The prevalence of arrhythmias increased with advancing age, reaching 48.3% in patients older than 80 years. Acute kidney injury occurred in 14.4%, with 1.7% requiring renal replacement therapy. Cytokine release syndrome occurred in 61.0% in 2021 and 62.1% in 2022, while immune effector cell–associated neurotoxicity syndrome was observed in 24.2% in 2022. Mean length of stay was 18.3 days, and inflation-adjusted hospitalization costs increased from $83,939 in 2017 to $378,507 in 2022. CONCLUSIONS: CAR T-cell therapy utilization increased substantially in the United States over the study period, with relatively low in-hospital mortality but notable cardiovascular complications, particularly arrhythmias. These findings highlight the importance of cardiovascular risk assessment and monitoring in patients undergoing CAR T-cell therapy. </p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13173972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147632566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improvement of cardiac function by Ivabradine in a doxorubicin-induced cardiomyopathy murine model is associated with a normal renal angiotensin II type I receptor expression but not with a reduction in fibrosis.","authors":"Gergana O Drumeva, Anne-Flore Plane, Daniil R Petrenyov, Paula A B Ribeiro, Cen Chen, Jean N DaSilva, François B Tournoux","doi":"10.1186/s40959-026-00469-z","DOIUrl":"10.1186/s40959-026-00469-z","url":null,"abstract":"<p><p>BACKGROUND: Ivabradine (IVAB) is an effective drug in patients with heart failure (HF). However, data in the context of chemotherapy-induced cardiomyopathy are limited. This study investigated the cardioprotective potential of IVAB in a doxorubicin (DOXO)-induced HF murine model, evaluating its effects on cardiac function, fibrosis, and its interaction with the renin-angiotensin system. METHODS : C57BLC/6 female mice (n = 36) completed the protocol and were allocated into 2 groups: control (CTRL, n = 4) and treatment by DOXO (n = 32). DOXO administration (4 mg/kg/week, intraperitoneal) was performed over 5 weeks and followed by a 10-week gavage treatment with either water (H2O), IVAB (10 mg/kg/day), or metoprolol (METO, 100 mg/kg/day). Cardiac and kidney remodeling were assessed by echocardiography, pathology (with fibrosis assessed by picrosirius red (PSR) staining), and in vitro 125I-[Sar1,Ile8]Angiotensin II autoradiography for the measurement of AT1R levels. RESULTS : After completion of DOXO injections, all mice demonstrated a lower cardiac function versus baseline (p < 0.0001). During therapy administration, only IVAB reduced heart rate (p < 0.0001) and improved cardiac function (p < 0.05). One week after the end of therapy , 1) cardiac function in IVAB group declined to levels similar to the other groups; 2) there was no difference in cardiac mass between groups, but fibrosis was increased in all DOXO-groups vs. CTRL (H2O +47%, p = 0.055; IVAB +90%, p < 0.001 and METO +47% in kidneys, p = 0.058); and 3) renal AT1R level was reduced only in the H2O group versus CTRL (-421%, p < 0.01), while IVAB and METO groups maintained renal levels comparable to controls. CONCLUSIONS: IVAB transiently improved systolic function in this model, but this benefit was not sustained after treatment cessation and did not prevent late structural fibrosis remodeling. Both IVAB and METO prevented the reduction of renal AT1R expression observed in DOXO treated animals. Overall, these findings indicate that HR-lowering therapy with IVAB alone is insufficient to prevent fibrotic remodeling, highlighting the need for longer-term studies to evaluate its sustained efficacy and impact on structural remodeling, and to assess its translational potential in managing DIC in patients. </p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13173794/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intrapericardial corticosteroid therapy for recurrent malignant pericardial effusion: a case series.","authors":"Nuri Lee, Yoojin Kim, Hyukjin Park","doi":"10.1186/s40959-026-00479-x","DOIUrl":"10.1186/s40959-026-00479-x","url":null,"abstract":"<p><p>BACKGROUND: Malignant pericardial effusion (PE) and subsequent effusive-constrictive pericarditis (ECP) are significant clinical challenges in patients with advanced cancer. CASE PRESENTATION: We report three patients with metastatic breast or lung cancer who experienced recurrent, life-threatening cardiac tamponade despite multiple pericardiocenteses (PCC) and systemic anti-inflammatory treatment (AIT). In all cases, pericardial disease recurred despite conventional management, while chronic systemic corticosteroid use led to debilitating adverse effects. Following complete drainage of the PE, a single high-dose bolus of 200 mg triamcinolone was administered via an intrapericardial catheter with a 12-h clamping protocol. This intervention was associated with sustained pericardial stabilization for 8 to 47 months across all three patients. Pericardial stabilization was maintained despite subsequent progression of the underlying malignancy. CONCLUSION: In this case series, high-dose (200 mg) intrapericardial corticosteroid therapy may represent a feasible therapeutic option for selected patients with recurrent malignant PE after prior PCC when systemic AIT is ineffective or poorly tolerated. </p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13151154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147527184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Arterial stiffness in long-term breast cancer survivors: a propensity score-matched analysis in primary prevention.","authors":"Renzo Melchiori, Miguel Rizzo, Noelia Brenzoni, Hector Gonzalez Aleman, Pamela Alarcon, Guido Garcia, Alejandro Hita, Sergio Gonzalez","doi":"10.1186/s40959-026-00476-0","DOIUrl":"10.1186/s40959-026-00476-0","url":null,"abstract":"<p><p>BACKGROUND: Breast cancer treatment may be associated with adverse cardiovascular effects. Pulse wave velocity (PWV) is a marker of arterial stiffness and a validated predictor of cardiovascular events. The aim of this study was to evaluate whether a history of breast cancer (HBC), beyond the first year after diagnosis, is associated with higher PWV in middle-aged women in a primary prevention setting. METHODS: Women aged 35 to 65 years evaluated at a cardiometabolic unit between September 2021 and March 2024 were included if valid PWV measurements obtained by automated oscillometry were available. Exclusion criteria comprised previous cardiovascular disease, chronic kidney disease stage > II, and inflammatory conditions. Participants were categorized according to HBC, defined as a diagnosis made at least one year prior to evaluation. A propensity score adjusted for age, hypertension, dyslipidemia, smoking status, physical inactivity, diabetes, obesity and use of statins was constructed, and 1:1 matching was performed. PWV (m/s) was the primary outcome. In addition, inverse probability weighting (IPW) analysis was conducted. RESULTS: A total of 2,318 women were analyzed (mean age 51.0 ± 7.3 years); 53 (2.3%) had HBC, with a median time of 67 months since diagnosis. PWV was significantly higher in women with HBC compared with those without cancer (7.85 ± 0.99 vs. 7.34 ± 1.09 m/s; p = 0.0008), with no significant differences in traditional cardiovascular risk factors. After matching, HBC was associated with a 0.34 m/s increase in PWV (95% CI: 0.24–0.45; p < 0.001). IPW analysis confirmed these findings. CONCLUSIONS: A history of breast cancer is associated with increased arterial stiffness independently of traditional risk factors, underscoring the relevance of vascular surveillance in breast cancer survivors. </p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13141257/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147520178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone.","authors":"Alan H Bryce, David Nimke, Christopher Young, Qiujun Shao, Nigel Rozario, Pinal Kamdar, Jasmina Ivanova, Irene Varghese, Maelys Touya","doi":"10.1186/s40959-026-00465-3","DOIUrl":"10.1186/s40959-026-00465-3","url":null,"abstract":"<p><p>BACKGROUND: Chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone (ABI) have a higher cardiovascular (CV) event-related hospitalization risk than those treated with enzalutamide (ENZA). This study aimed to assess CV event risk in chemotherapy-naïve patients with mCRPC treated with ENZA or ABI and to provide outcome data based on CV disease (CVD) history using the US Medicare database. METHODS: Chemotherapy-naïve patients with mCRPC (≥ 65 years) who initiated ENZA or ABI (September 2014 − May 2017) were included. The primary endpoint was a 4-point major adverse CV event (MACE; a composite of acute myocardial infarction, stroke, unstable angina/revascularization, and heart failure). Atrial fibrillation, venous thromboembolism, and all-cause death were also analyzed. Further, the risk of adverse CV outcomes was compared between ENZA- and ABI-treated cohorts (overall population and by CVD-risk subgroup). Sensitivity analysis was performed using a 5-point MACE (4-point MACE plus CV-related death) as the endpoint. RESULTS: Of 6319 patients (ENZA: 2934; ABI: 3385), 2913 propensity score-matched patients were included from each group (prior CVD: 76%). ABI was associated with a significantly higher risk of 4-point MACE (hazard ratio [HR]: 1.12; 95% confidence interval [CI]: 1.02–1.24; P = 0.028), unstable angina/revascularization (HR: 1.13; 95% CI: 1.01–1.26; P = 0.041), atrial fibrillation (HR: 1.73; 95% CI: 1.31–2.29; P < 0.001), venous thromboembolism (HR: 1.37; 95% CI: 1.02–1.85; P = 0.037), and all-cause death (HR: 1.13; 95% CI: 1.07–1.19; P < 0.001) versus ENZA. In the sensitivity analyses, these results were confined to the subgroup of patients with a history of CVD. CONCLUSIONS: ABI-treated patients with mCRPC had a higher risk of developing composite 4-point MACE and other CV events than ENZA-treated patients. </p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13122974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Paediatric cardio-oncology: strengths and challenges in developing a collaborative care pathway between oncologists and cardiologists. The Italian experience.","authors":"Alice Pozza, Elena Bennati, Nicoletta Bertorello, Anna Balducci, Gabriele Rinelli, Arcangelo Prete, Rossella Mura","doi":"10.1186/s40959-026-00470-6","DOIUrl":"10.1186/s40959-026-00470-6","url":null,"abstract":"<p><p>BACKGROUND: Paediatric cancer survival rates continue to improve with overall long-term survival now over 80%. A significant proportion of conventional and novel cancer therapies have cardiovascular toxicities which become increasingly relevant as long-term survival improves. At present, within the Italian healthcare setting, a systematic approach to the detection and management of cardiotoxicity in paediatric patients is lacking, and most available recommendations are extrapolated from adult evidence. This study aimed to assess current practices in cardiovascular care delivery for childhood cancer patients and survivors in Italy. MATERIALS AND METHODS: An online 23-item nation-wide questionnaire was created by the Italian Society of Paediatric Cardiology (SICP) and the Italian Paediatric Haematology-Oncology Association (AIEOP) to explore the care, management and surveillance tools used to manage cardiotoxicity among paediatric patients and survivors. The survey was distributed among physicians within the AIEOP network. RESULTS: Thirty-six of the 49 centres answered to the survey (response rate 73.4%). Most respondents (n = 30, 83.3%) indicated that children are regularly screened for cardiotoxicity. The cardiological evaluation included the following echocardiographic methods to guide decisions on whether to start cardioprotective strategies or modify oncologic treatment protocols: Simpson biplane ejection fraction (EF) (n = 23, 63%) and left ventricle (LV) global longitudinal strain (GLS) (n = 5, 13.9%). CONCLUSIONS: Results reveal significant heterogeneity in clinical practice among different centres. This report unveils the urgent need for unified recommendations to improve detection and long-term follow-up of cardiotoxicity to enhance cardiologic outcomes of paediatric cancer patients. </p>","PeriodicalId":9804,"journal":{"name":"Cardio-oncology","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13130443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}